Phase I Study of Carbon Ion Radiotherapy and Image-Guided Brachytherapy for Locally Advanced Cervical Cancer
-
- Yuya Yoshimoto
- Gunma University Heavy Ion Medical Center, Gunma University, 3-39-22 Showa, Maebashi, Gunma 371-8511, Japan
-
- Noriyuki Okonogi
- Gunma University Heavy Ion Medical Center, Gunma University, 3-39-22 Showa, Maebashi, Gunma 371-8511, Japan
-
- Ken Ando
- Gunma University Heavy Ion Medical Center, Gunma University, 3-39-22 Showa, Maebashi, Gunma 371-8511, Japan
-
- Tomoaki Tamaki
- Gunma University Heavy Ion Medical Center, Gunma University, 3-39-22 Showa, Maebashi, Gunma 371-8511, Japan
-
- Shingo Kato
- Department of Radiation Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan
-
- Takashi Hirakawa
- Department of Obstetrics and Gynecology, Gunma University Graduate School of Medicine, 3-39-22 Showa, Maebashi, Gunma 371-8511, Japan
-
- Kazutoshi Murata
- Gunma University Heavy Ion Medical Center, Gunma University, 3-39-22 Showa, Maebashi, Gunma 371-8511, Japan
-
- Tatsuya Kanuma
- Division of Gynecology, Gunma Prefectural Cancer Center, 617-1 Takahayashi-nishi, Ota, Gunma 373-0828, Japan
-
- Takashi Minegishi
- Department of Obstetrics and Gynecology, Gunma University Graduate School of Medicine, 3-39-22 Showa, Maebashi, Gunma 371-8511, Japan
-
- Takashi Nakano
- Gunma University Heavy Ion Medical Center, Gunma University, 3-39-22 Showa, Maebashi, Gunma 371-8511, Japan
-
- Tatsuya Ohno
- Gunma University Heavy Ion Medical Center, Gunma University, 3-39-22 Showa, Maebashi, Gunma 371-8511, Japan
-
- Shin-ei Noda
- Gunma University Heavy Ion Medical Center, Gunma University, 3-39-22 Showa, Maebashi, Gunma 371-8511, Japan
書誌事項
- 公開日
- 2018-09-18
- 資源種別
- journal article
- 権利情報
-
- https://creativecommons.org/licenses/by/4.0/
- DOI
-
- 10.3390/cancers10090338
- 公開者
- MDPI AG
説明
<jats:p>A phase I study was performed to determine the recommended dose of carbon ion radiotherapy and 3D image-guided brachytherapy for histologically confirmed stage II (≥4 cm), III, or IVA cervical cancer. Dose-limiting toxicities (treatment-related toxicities occurring within three months from the start of carbon ion radiotherapy) included Grade 3 non-hematological toxicity, Grade 4 hematological toxicity, or interruption of treatment for more than two weeks due to treatment-related toxicities. Carbon ion radiotherapy consisted of whole-pelvic irradiation with 36.0 Gy (relative biological effectiveness) in 12 fractions and local boost with 19.2 Gy in four fractions for the primary site, and for positive lymph nodes. Three sessions of three-dimensional (3D) image-guided brachytherapy were administered after completion of carbon ion radiotherapy. Weekly cisplatin at a dose of 40 mg/m2 was given concurrently. At a dose level of one, a total rectosigmoid D2cc dose between 67.2 Gy and 71.3 Gy at a biological equivalent dose of 2 Gy per fraction from carbon ion radiotherapy and 3D image-guided brachytherapy was prescribed. Six patients were enrolled into this dose level. No patients developed the pre-defined dose-limiting toxicities. For late toxicities, however, one patient developed Grade 3 rectal hemorrhage requiring transfusion at 10 months after treatment. The median survival time was 50.0 months for the five surviving patients. No further dose escalation was performed, and we determined the dose of level one as the recommended rectosigmoid dose. Although our results are preliminary, the study regimen encourages further investigation (registration: UMIN000013340).</jats:p>
収録刊行物
-
- Cancers
-
Cancers 10 (9), 338-, 2018-09-18
MDPI AG
